phd haematology australia

• About the RACP
• What is a physician or paediatrician?
• College structure
• Board and governance
• College Council
• Accreditation
• Consumer Advisory Group
• Special Interest Groups
• Multi-factor authentication
• Our heritage
• Get involved
• Careers at RACP
• Medical positions
• Congress 2024
• The President's Message
• RACP 2024 Elections
• Media releases
• Expressions of Interest
• RACP in the media
• Quick facts
• Represent your profession
• Policy and Advocacy Priorities
• Policy and Advocacy Library
• CPAC reports
• Voice to Parliament
• Make It The Norm
• Division, Faculty and Chapter Priorities
• Regional Committee Priorities
• Donate to Foundation
• Research Awards and Career Grants
• College and Congress prizes
• Division, Faculty and Chapter Awards & Prizes
• Regional Awards & Prizes
• Indigenous Scholarships & Prizes
• International Grants
• Student Scholarships & Prizes
• Terms and Conditions
• Our recipients

In this section:

• Australian Capital Territory AIM
• New South Wales AIM
• Northern Territory AIM
• Training pathways
• Becoming a Fellow
• Basic Training
• Advanced Training
• Basic Training Registration
• RACP Benefits
• College and Congress Prizes
• Division, Faculty and Chapter Awards
• Indigenous Scholarships and Prizes
• College Fees Terms and Conditions
• Fee Reimbursement Initiative
• 2024 fee increase FAQs

If you are looking to start your journey to becoming a physician, make an enquiry today!

• Adult Internal Medicine
• Paediatrics & Child Health
• Moving to Advanced Training
• Application dates

Recognition of Prior Learning

• Supervisors and Committees
• Training portals
• Advanced Training Programs
• Curricula Renewal
• Advanced Training Forum
• Professional Practice Framework
• Curriculum Advisory Group
• Interrupting or withdrawing from training
• Part-time and variations in training
• Trainee responsibilities
• Specialist Training Program Initiative
• Basic Training accredited settings
• Divisional Written Examination
• Divisional Clinical Examination
• AFOEM Stage A Written Examination
• Accredited settings
• Education policies
• Educational research and evaluation
• Professional behaviour
• AFOEM resources
• AFPHM resources
• College Learning Series
• Physician Training Survey
• Advanced Training Accredited settings
• College Ceremony
• New Fellow Survey
• Supervisor Professional Development Program
• Basic Training Supervision
• Advanced Training Supervision
• Position design and posting
• Applications
• The RACP CPD Home
• 2023 MyCPD Framework
• CPD resources
• Training setting obligations
• Spaced Learning
• RACP Online Learning
• RACP Quarterly magazine
• Affiliate and associate members
• Area of Need assessment
• Short-term specialist training
• Vocational registration

Clinical Haematology

Covid-19 interim changes to program requirements.

In 2023, you're expected to satisfactorily complete all training program requirements. If you’re unable to complete training requirements due to COVID-19, see interim changes to requirements  and education and training principles , and advise your training committee as soon as possible.

You're viewing the 2023 – 2024 handbook

Program overview, apply or re-register, training requirements, forms and resources.

Program updates

The Advanced Training in Clinical Haematology Program is evaluated biennially by the Committee for Joint College Training (CJCT) in Haematology and the Aotearoa New Zealand Joint College Training Subcommittee (JCTS) in Haematology to ensure that it’s in line with educational best practice. Changes in program requirements may occur and could impact your training plan. You must ensure you’re following the correct requirements during your training.

Entry requirements

Prospective trainees must have:

• completed RACP Basic Training, including Written and Clinical Examinations
• a current medical registration
• been appointed to an appropriate Advanced Training position

New and current trainees need to apply for Advanced Training each year.

Advanced Training in Clinical Haematology requires 3 years (36 months) of full-time equivalent (FTE) training.

Once you've completed all requirements of your training and the CJCT or JCTS in Haematology has recommended you for admission, the College will invite you to apply for Fellowship of the Royal Australasian College of Physicians.

See Becoming a Fellow  for information on admission to Fellowship.

As a Fellow in active practice in Australia, Aotearoa New Zealand or overseas, you’ll need to meet the annual requirements of the Continuing Professional Development program .

Australian trainees can complete their registration online.

Apply online

If the online application is closed, email an application form   (DOC) to [email protected]

Aotearoa New Zealand

Aotearoa New Zealand trainees must email an application form   (DOC) to [email protected]

Nominating eligible supervisors

From mid-2023, you’re required to nominate eligible supervisors  who meet the supervision requirements of the training program.

You can find a list of eligible supervisors:

• in the supervision section of your online registration form

The MyRACP list is not available for post-Fellowship trainees. Post-Fellowship trainees can check the list in their online registration form or contact us  to confirm supervisor eligibility.

Application deadlines

15 February | first half or whole of the current year

31 August | second half of the current year

15 December | first half or whole of the following year

30 April | May to August rotations

30 June | second half of the current year

You're responsible for organising all necessary documentation for submission by the deadline. We recommend that you keep a copy of your application for future reference.

See program key dates for trainees and supervisors.

Late applications

Late applications will be considered up to 1 month after the deadline.

Applications received 1 month after the deadline won’t be considered unless exceptional circumstances can be demonstrated in line with the Special Considerations for Assessment Policy .

Late applications may incur a fee.

Late fees won't apply if supervisor approval is pending after the deadline.

The standard annual membership fees apply.

Visit MyRACP to pay or view previous training program payments.

About your training position

Core training must be undertaken at accredited settings .

Once you have secured a training position, you must prospectively apply for approval as per the  Progression through Training Policy .

The College is not involved in the recruitment and selection of trainees. Our role is to set and monitor standards for selection and provide advice to settings and their selection committees.

Training approval and certification

Approval of training periods are determined by the Committee for Joint College Training (CJCT) in Haematology and the Aotearoa New Zealand Joint College Training Subcommittee (JCTS) in Haematology. To be approved, your individual training program must be consistent with the training requirements and appropriate for the stage of training you have reached.

Upon completion of each rotation or calendar year of training, the CJCT/JCTS reviews your progress according to the training requirements. If you have satisfactorily completed all training requirements, the CJCT/JCTS will certify that training period.

Training variations

See variations in training  for processes covering dual, joint, conjoint and post-Fellowship training.

See flexible training options for information on part-time training, interruptions to training, withdrawing from training and time limits.

Rotation or supervision changes

Changes to your rotation require you to re-submit an application form (if online registration is closed) to your training committee as soon as possible. This includes any changes to sites, dates of rotations and flexible training arrangements.

Change to your supervision must be notified as soon as possible by submitting a Supervisor Details Amendment Form   (DOC) .

Some changes may require a review of the approval decision and can affect the certification of your training.

More information

Overseas specialists Trainee responsibilities

At the end of your Advanced Training in Clinical Haematology, you’ll have completed 36 months of certified training time consisting of work-based learning and assessment tools.

The PREP teaching and learning activities are designed to support you in your reflective practice and self-directed learning. A variety of teaching and learning activities and assessments are used, catering to a range of learning needs, styles and situations that may arise in your workplace training.

See forms and resources for the training program curricula.

Requirements overview

Training program (core training — 30 months minimum | non-core training — 6 months maximum), supervision.

1 x supervisor per rotation, who is a Fellow of the RACP

1 x supervisor per rotation, who can be a Fellow of the RACP

Teaching and learning

2 x Learning Needs Analysis per training year

Assessments

2 x Case-based Discussions per training year

2 x Mini-Clinical Evaluation Exercises per training year

1 x Supervisor’s Report per rotation (2 per 12-month rotation — full-time and part-time trainees)

Non-core training (6 months maximum)

1 x supervisor who is a Fellow of the RACP per rotation

1 x supervisor who can be a Fellow of the RACP per rotation

Advanced Training summary

After 36 months of certified training time, you will have completed:

• 24 months of core clinical training
• 6 months of core laboratory training
• 6 months of non-core training
• 1 x Advanced Training Research Project (trainees who commenced in 2017 onwards)
• 1 x Haematology Research Project (trainees who commenced before 2017)
• Australian Aboriginal, Torres Strait Islander and Māori Cultural Competence and Cultural Safety online course (trainees who commenced in 2023 onwards)
• Developmental and Psychosocial Training (Paediatrics & Child Health trainees only)
• Paediatric Advanced Life Support course (Aotearoa NZ Paediatrics & Child Health trainees only, if not completed)

2023-24 program updates

In your 2023 and 2024 training year, these requirement changes apply.

Work-based learning and assessment requirements

Time-based requirements.

The Advanced Training Program in Clinical Haematology allows adequate time for you to gain the necessary learning experiences across a range of relevant rotations during your 3-year total training period (36 months FTE).

Trainees commencing in 2022 onwards

A maximum of 24 months may be spent at one setting.

Trainees may complete all training within a network if they rotate between independent sites.

Training rotations

Night rotations do not satisfy the time-based requirement for core and non-core training.

Non-core training

Your non-core training can be undertaken in clinical training in disciplines relevant to haematology, which may include medical oncology, palliative medicine or infectious diseases. Relevant disciplines will be considered for prospective approval on a case-by-case basis.

Research relevant to haematology can also be approved.

Training time

At least 24 months of total training time (core and non-core) of Advanced Training in Clinical Haematology must be undertaken in Australia and/or Aotearoa New Zealand. This is to ensure that you receive adequate exposure to local practices and health services.

Trainees who commenced before 2022

At least 12 months of core Advanced Training in Clinical Haematology must be undertaken in Australia and/or Aotearoa New Zealand. This is to ensure that you receive adequate exposure to local practices and health services.

Program key dates

January — march.

• 31 January |  Previous year’s Supervisor’s Report and all PREP learning and assessment tools due (trainees not applying for Fellowship in December)
• 15 February | Applications for Approval of Advanced Training for the first half or whole of the current year due
• 31 March |  Advanced Training Research Project may be submitted

Case-based Discussion

Learning needs analysis, april — june.

• 15 June |  Advanced Training Research Project may be submitted
• Learning Needs Analysis self-evaluation

Mini-Clinical Evaluation Exercise

July — september.

• 15 July | Supervisor’s Report due
• 31 August | Applications for Approval of Advanced Training for the second half of the year due
• 15 September | Advanced Training Research Project due (trainees who commenced in 2017 onwards)
• 15 September | Haematology Research Project due (trainees who commenced before 2017)

October — December

• 15 October | Supervisor’s Report, Trainee’s Report and all PREP learning and assessment tools due (trainees eligible for Fellowship in December)

December — February 

• 15 December | Applications for Approval of Advanced Training for the first half or whole of the following year
• 15 December | Advanced Training Research Project due (trainees who commenced in 2017 onwards)
• 15 December | Haematology Research Project due (trainees who commenced before 2017)
• 15 December |  Supervisor’s Report and all PREP tools due

March — May

• 30 April |  Applications for Approval of Advanced Training for May to August rotations due

June — August

• 30 June | Applications for Approval of Advanced Training for second half of the year due
• 30 June |  Supervisor’s Report due

September — November

• Learning Needs Analysis self-evaluation

A work-based learning and assessment tool requirement stipulates what you must achieve as part of your training program.

Type of assessment

Formative: Focuses on learning through feedback and guidance, which assists trainees and supervisors in the formal feedback discussion through prompting discussion of or highlighting areas of a trainee’s performance. Assessments are based on existing workplace-based assessment methods and are best practice in medical education.

Summative: Focuses on judgements about trainee progression, resulting in pass or fail decisions on a trainee’s performance.

Advanced Training Research Project

Requirement for trainees who commenced in 2017 onwards.

The Advanced Training Research Project (ATRP) is a report on a project that you have had significant involvement in designing, conducting of research and analysis of data. It enables you to gain experience in:

• research methods
• interpretation of research literature
• participation in research at some stage of your career
• developing quality improvement skills

ATRPs are not required to be specialty-specific but must be broadly relevant to your area of specialty. ‘Broadly relevant’ is defined as topics that can enhance, complement and inform your practice in the chosen specialty.

The ATRP, introduced to most trainees who commenced after 2017, addresses wide variations in purpose, type, quantity and assessment criteria across the RACP Training Programs. An ATRP submission provides evidence of the skills of:

• considering and defining research problems
• the systematic acquisition, analysis, synthesis and interpretation of data
• effective written communication

The ATRP requirement must be undertaken and completed during your Advanced Training. If you are dual training, you only need to complete one ATRP over the course of Advanced Training.

Review your training program requirements to confirm whether there are any additional research requirements beyond completing your ATRP. 

Requirements

Requirement.

1 x Advanced Training Research Project to be completed in any year before the end of Advanced Training.

It's recommended that you submit your research project in your penultimate year. If you submit in your final year, you may not have enough time to address any feedback or resubmit if needed. This could delay your progression of training or admission to Fellowship.

Advanced Training Research Project cover sheet (DOC)

You can apply for Recognition of Prior Learning (RPL) for the ATRP requirement if you can demonstrate that you’ve successfully completed a:

• research doctoral degree, like MD or PhD
• Master's/higher degree by research
• major project completed through a Master's by coursework
• publication of research as first author in a peer-reviewed, indexed medical scientific journal

Research completed through your primary medical qualification is not eligible for RPL.

Applications for recognition of research completed prior to entry into training are considered in accordance with our Recognition of Prior Learning Policy .

Accepted project topics

Focus areas to be accepted across all categories are:

• human subjects, populations and communities and laboratory research
• epidemiology
• medical humanities
• areas of study which can be applied to care of patients or populations

You must apply for RPL for research activities within 6 months of commencing your first approved rotation in your Advanced Training Program. You'll need to submit evidence of satisfactory completion with your application.

• complete the Recognition of Prior Learning application form (DOC)
• Advanced Training (Australia): [email protected]
• Advanced Training (Aotearoa New Zealand): [email protected]  

Your Advanced Training Committee or Subcommittee, which reviews all RPL applications, will contact you about the outcome.

Exemption during training

Exemptions for alternative research in progress during your Advanced Training will be assessed for suitability against the ATRP guidelines and marking criteria. You can apply for an exemption if you are undertaking a:

• Master’s/higher degree by research
• major project completed through a Master’s by coursework

An exemption can be applied for trainees who undertook this work whilst on an interruption of RACP training.

A PhD and higher degree by research completed through an Australian or Aotearoa New Zealand University will automatically satisfy the Advanced Training research requirement without the need for review by project markers.

If you have completed a Master’s by coursework, submit the course outline, transcript and a certified copy of evidence of completion (for example a testamur/certificate). The marks and grade for each unit must be legible. All supporting documentation will be reviewed to determine whether they meet the learning outcomes of the research requirement. If it's determined that the learning outcomes of the research requirement criteria are met, your completion date of the research requirement is the date the transcript is received at the College.

Please submit this information as soon as possible to allow time for review and to avoid delays in recommendation to Fellowship.

An application for exemption may be submitted to the College at any time.

• complete the Advanced Training Research Project exemption form   (DOC)
• Advanced Training (Aotearoa New Zealand): [email protected]

Exemption is granted only when the evidence presented fulfils the research requirements, separate to whether your research or coursework is relevant to your current specialty. You will be required to submit evidence of satisfactory completion before the end of your Advanced Training.

Accepted project formats

Three research project types are accepted:

• systematic review

Additional project formats may be considered provided they meet the Advanced Training Research Project (ATRP) guidelines and marking criteria. Trainees and supervisors seeking additional format approval need to provide justification as to how the project submission meets the criteria.

Research in human subjects, populations and communities or laboratory research

This project type also includes epidemiology, education, leadership, medical humanities and areas of study which can be applied to care of patients or populations.

Step-by-step: Research in human subjects, populations and communities or laboratory research

1. General preparation

• Identify a supervisor and review the ATRP guidelines.
• Develop skills in scientific writing to apply for grant support, publish scientific and medical papers.

2. Identify the problem and formulate research questions

• Consider and define a health-related problem.
• Review, analyse and synthesise evidence related to the existing literature, or your current practice, to identify research gaps and formulate research questions or hypotheses.

3. Develop the research design

• Convert information needs into answerable questions and clearly identify the specific aims of a study designed to address the question.
• Identify an appropriate research method and techniques.
• Identify the ethical issues arising from conduct of the study.
• Obtain ethics approval from the appropriate body, if required.

4. Collect or identify data to achieve the study objectives

• Apply quantitative or qualitative methods.

5. Write up research

• Appraise and synthesise the research findings in consideration of the research objectives and hypotheses.
• Set findings within the context of the wider literature on the topic.
• Apply the results of the study to practice.
• Demonstrate effective and succinct written communication.
• Outline how research should and could contribute to the practice of evidence-based medicine.
• Assess strengths, weaknesses and limitations of the research project.
• Reference using a consistent style.

6. Self-reflection

• Evaluate your performance.
• Discuss your performance with your supervisor — consider any issues that arose during the research project and how the findings might change your practice.

An audit project aims to assess, evaluate and improve the quality of healthcare through the systematic review of practice. A specific component of practice to be reviewed is identified and local performance is assessed against specific criteria in relation to the gold standard.

If a repeated audit isn’t possible due to time constraints, then a plan for implementing, measuring and sustaining improvements must be presented.

Your audit should be of an area of interest to you. Look at opportunities to audit a novel project or program within your training setting.

The size of your audit is dependent on the topic and nature of the audit undertaken. The presentation of the audit must adhere to the standards for presentation of research, including the suggested word count.

You must demonstrate a clear understanding of the audit cycle, with evidence of how your work will lead to an improvement in clinical practice.

Step-by-step: Audit

Follow the paradigm of ‘joined-up research’, which begins by assessing a problem, moving on to implementing change and completing the circle by evaluating change over an appropriate period.

1. Identify a topic that is important to audit.

2. Review the literature and other relevant information to determine standards against which to audit.

3. Develop audit criteria that will measure performance against the agreed standard.

4. Collect and analyse data and report results.

5. Reflect on results and develop improvement plan.

6. Implement improvement plan.

7. Repeat data collection to measure improvement.

Systematic review

A systematic review is a method of critically appraising bodies of research studies with a high level of rigour. Systematic reviews are different to narrative reviews and expert commentaries because they use a well-defined protocol to ensure high coverage of all relevant information and can be replicated easily. A standard, published protocol, such as the PRISMA guidelines could be used.

For ATRPs, the systematic review should be conducted in an area of relevance of your practice.

Step-by-step: Systematic review

1. Define the review question and rationale behind question.

2. Develop inclusion and exclusion criteria for including studies, search for studies and explain search syntax, define search strategy — for example a brief description of PICO, identify and defend databases searched.

3. Assess study quality.

4. Select studies and collect data.

5. Assess risk of bias of included studies.

6. Analyse data.

7. Interpret results and draw conclusions.

RACP Online Learning Resource: Research Project

Presentation guidelines

You're encouraged to present your Advanced Training Research Project (ATRP) orally at hospital, state or national meetings and submit your work for publication in an appropriate peer-reviewed journal. It should meet the requirements of that journal and instructions to authors for the journal should be submitted with the ATRP.

The ATRP word limit should be appropriate to the study type:

• quantitative research | up to 3500 words
• qualitative research | up to 5000 words

You must comply with the Academic Integrity in Training Policy .

Your ATRP presentation should contain:

1. Abstract | approx 10% of word count

• concise summary of the background, aims, methods, results and conclusions

2. Introduction

• discussion and placement of the research in context of published literature
• critique of literature if there are alternative views
• define the research aim, questions and hypotheses

4. Methodology

• describe the methods used in enough detail to allow it to be replicated

5. Statistical analysis

• perform appropriate statistical analysis of the data
• present the results in figure and tabular format to the standard of published literature
• include figure and table legends with a brief description of your data and statistical analysis

7. Discussion

• discuss and interpret the results
• discuss the results in context of published literature - for example, do your results support or disagree with published literature and do they enhance what is already published?
• consider the limitations of the study

8. Conclusion

• brief conclusion of the research
• potential project improvements if you were to repeat the study
• future steps/directions

9. Reference list

RACP Online Learning Resource: Research Project Research Project checklist and planner   (XLS)

Submission guidelines

When electronically submitting your Advanced Training Research Project (ATRP), you’re to provide:

• an Advanced Training Research Project cover sheet (DOC)
• Turnitin similarity report

The Turnitin submission and reporting process is outlined in the project cover sheet.

Email your research project submission to [email protected]

About Turnitin

Turnitin is an originality and plagiarism detection tool, which compares projects against electronic texts from the Internet, published works and assignments previously submitted to Turnitin by other users.

The similarity report you’re to obtain from Turnitin provides you the opportunity to make any changes prior to submitting your project to the College for marking.

An updated similarity report must be submitted with the project if changes are made. If an updated report isn’t submitted, the College will obtain a report on your behalf and you won’t have the opportunity to make changes.

Find out more about Turnitin detection tool.

For most Advanced Training Programs, submission of your research project is due by your second last year of training to ensure enough time for marking the project and the opportunity to resubmit if required. Refer to the requirements for submission dates.

To request an extension, contact your specialty’s Education Officer .

If you don’t meet the prescribed deadline, it could delay your progression of training, or if you are near the end of training, it can delay your admission to Fellowship. It’s important to plan early and submit your project as soon as possible.

Advanced Training Research Project cover sheet (DOC) Advanced Training Research Project marking criteria (DOC) Research Project checklist and planner   (XLS)

Marking outcomes

Research projects are independently marked by 2 assessors using the Advanced Training Research Project marking criteria (DOC) common to all Advanced Training Programs.

In the case that the assessors cannot reach agreement, the research project is sent to a third assessor who will determine an outcome.

There are 3 grading outcomes that a project reviewer can make:

• Pass — meets expected standard, below expected standard in no more than 1 criterion
• Resubmit — 2 or more areas below the expected standard
• Fail — doesn’t meet any of the criteria for a research project

You’ll receive the outcome of your project within approximately 8 to 12 weeks of submission to the College. Delays in receiving project outcomes can happen between September and January, when the majority of project submissions are expected to occur.

If your project is marked as ‘resubmit’, you’ll have 2 more opportunities to resubmit the same project to assessors with revisions. If you’re dissatisfied with the outcome following 2 resubmissions, you can request for 2 new assessors to mark the project.

You can also request 2 new assessors to mark your project if it’s marked as a ‘fail’ in the first instance.

In this stage of marking, there are only 2 marking outcomes new assessors can provide — ‘pass’ or ‘fail’. If your project is marked as a ‘fail’ by the 2 new assessors, you cannot resubmit again and will need to complete a substantially new project to meet your ATRP requirement.

Advanced Training Research Project marking criteria (DOC)

Project supervisor's role

Your research project supervisor guides you with your project choice, method, data analysis and interpretation, and quality of written and oral presentation.

A project supervisor requires specific skills and experience and likely won't be your training rotation supervisor. To find an appropriate supervisor:

• explore the work of notable researchers in your hospital or network who may be able to help you find suitable potential project supervisors
• ask your training rotation supervisor for advice, relevant contacts or to direct you to another colleague who can
• attend research groups or events held at your hospital to get ideas, meet research supervisors and network with trainees

These steps are important if you’re at a small training site with limited research opportunities.

If you end up with a project supervisor and a training rotation supervisor, clear communication between both supervisors is important so that they’re both aware of your progress in your research project work.

A project supervisor should:

• familiarise themselves with the guidelines and marking standards
• recommend colleagues to assist with supervision, if necessary
• meet with you early in the period of supervision to clarify the research project goals and requirements
• consider and provide feedback regarding the merits of the proposed research project early in the process
• ensure that your planned research project is feasible and of a suitable standard
• review the feasibility of your developed project timeline
• clarify access to statistical support or other resources required
• monitor progress at regular intervals
• review the research project prior to submission, ensuring it’s of an acceptable standard
• support you to find a forum to present the research project
• approve the research project prior to submission to indicate that the proportion of work attributed you is correct

When selecting a research project supervisor, choose someone who:

• aligns with your goals
• is an expert in the area of your research
• is available for regular meetings or other correspondence
• is interested in providing mentorship and guidance on the project
• is interested in the topic of the proposal
• provides constructive criticism on completed work, such as abstracts and academic writing
• enjoys sharing knowledge, such as laboratory or technical skills, academic research and writing skills
• is experienced supervising research students

You should establish manageable expectations and practice open and clear communication with your research project supervisor from the beginning.

A Case-based Discussion (CbD) is a work-based assessment and Advanced Training Program requirement used to evaluate your professional judgement in clinical cases.

A CbD involves a comprehensive review of a clinical case or cases between you and an assessor. After the CbD, the assessor provides constructive feedback to help you improve and structure your future learning.

The CbD aims to:

• guide your learning through structured feedback
• improve clinical decision making, clinical knowledge and patient management
• provide you with an opportunity to discuss their approach to the case and identify strategies to improve your practice
• enable your assessor to share their professional knowledge and experience

An assessor can choose any case or cases where you'll play a significant role in clinical decision-making and patient management. The discussion should reflect your level of experience and be linked to your Advanced Training Curriculum.

The discussion may focus on a single complex case or a series of cases covering a wide range of clinical areas. Areas may include:

• record keeping
• history taking
• clinical findings and interpretation
• management plan
• follow-up and future planning

Step-by-step: Case-based Discussion

• Arrange a CbD with your assessor.
• Your assessor will choose an appropriate case or cases.
• Confirm the chosen case or cases with your assessor.
• Provide your assessor with a CbD rating form (PDF).
• Discuss the case or cases with your assessor – allow for at least 30 minutes. Note: Your assessor will be making notes and ratings on the CbD rating form during this discussion.
• Your assessor provides you feedback following your CbD – allow for at least 10 minutes.
• You and your assessor sign the CbD rating form.
• Enter the data from your completed CbD form into the online CbD tool via your relevant training portal: Advanced Training Portal  | AFRM Portal  | AFPHM Portal  | AFOEM Portal
• Submit a copy of your completed form to your assessor through the online CbD tool in your training portal.

2 x Case-based Discussions (CbD) to be completed each training year (1 per 6-month period), early in the rotation

Australia: 31 January in the following year.

Aotearoa New Zealand: Due at the end of each rotation.

In your final year, CbDs are due 15 October.

Submit your CbD rating form data via the Advanced Training Portal .

Case-based Discussion rating form (PDF)

Cultural Safety

Requirement for trainees who commenced in 2023 onwards.

Specialist training requires you to:

• examine your own implicit biases
• be mindful of power differentials
• develop reflective practice
• undertake transformative unlearning
• contribute to a decolonisation of health services for Indigenous peoples

The Australian Aboriginal, Torres Strait Islander and Māori Cultural Competence and Cultural Safety online course  teaches best practice medicine for Aboriginal, Torres Strait Islander and Māori patients through reflection on your own cultural values and recognition of their influence on professional practice.

RACP Online Learning: Australian Aboriginal, Torres Strait Islander and Māori Cultural Competence and Cultural Safety

1 x Australian Aboriginal, Torres Strait Islander and Māori Cultural Competence and Cultural Safety online course *

* If not completed during Basic Training.

Certification

You'll immediately receive your certificate on RACP Online Learning when you complete the course. Certification will appear in your Advanced Training Portal in July the year you complete the course.

You must complete the course by the end of your Advanced Training however it’s recommended you complete it within your first year.

Developmental and Psychosocial Training

Requirement for paediatrics & child health trainees only.

Developmental and Psychosocial (D&P) Training assists trainees to develop a sophisticated understanding of child development, encompassing physical, cognitive, emotional, behavioural and social areas, which should be gained from the perspective of the child within the family and in the context of the community.

A mandatory period of D&P Training for all paediatricians was introduced to ensure that the changing nature of paediatric practice is reflected in the training programs.

Prospectively apply for D&P Training via the Advanced Training online registration .

Allowed rotations

• Child and adolescent mental health
• Child protection
• Community paediatrics
• Developmental/behavioural paediatrics
• Disability/rehabilitation paediatrics
• Palliative medicine

These areas reflect a holistic approach to the health problems of children and young people. An understanding of the roles and inter-relationships of many allied health and community-based services, in a way that distinguishes them from experience in organ-based specialties, is required.

Approved training options

A prospectively approved psychosocial training position (6 months).

The 6-month training program can be completed in one of these formats:

• 2 x 3-month terms
• 1 x 6-month block
• a continuous part-time position, such as 2.5 days a week for 12 months *

A prospectively approved rural position (6 months)

Complete the 6-month training comprised of a documented weekly program in the psychosocial training areas with an appropriate level of supervision.

Attendance at a prospectively approved clinic

• 2 x sessions a week for 18 months
• 1 x session a week for 3 years

You must also complete an approved learning module.

Approved clinics

An approved clinic is determined to be a clinic where other health and/or educational professionals are involved, and supervision is directed by a paediatrician who is experienced in one or multiple areas of D&P Training, such as behaviour, development, rehabilitation and child protection.

Approved learning module options

An approved learning module includes one of the following options:

• Evidence of attendance at a lecture series at a recognised institution, related to the D&P Training areas.
• 3 x referenced case reports/essays demonstrating comprehensive understanding of 3 different issues in the areas of psychosocial training – for example rehabilitation or community paediatrics (1500 to 2000 words each).
• Completion of the Griffith Mental Developmental Scales course.

Other prospectively approved modules may be considered.

Advanced Training Developmental and Psychosocial Training Supervisor's Report form (DOC)

1 x 6-month period of training during your Basic or Advanced Training

You must complete your Developmental and Psychosocial Training by the end of Advanced Training.

At the end of your rotation, you must submit an Advanced Training Developmental and Psychosocial Training Supervisor's Report   (DOC) for certification.

A satisfactory Supervisor’s Report for Developmental and Psychosocial (D&P) Training is required for your training to be certified.

You must nominate a supervisor for your D&P Training component during your Advanced Training.

Advanced Trainees who want their D&P Training rotation to count towards their specialty training time must also submit a specialty Supervisor’s Report.

Prospectively apply for D&P Training via your Advanced Training registration process .

• Adolescent medicine
• Child protection and adolescent psychiatry

Rotations not suitable for D&P Training:

• Paediatric gastroenterology *
• Paediatric neurology **

Alternatively, you can gain the required training by managing suitable cases over a longer period with appropriate supervision. Your training must be documented in a logbook.

You must keep a record of at least 12 cases you've personally managed under supervision.

In your logbook, your entries must cover a range of conditions:

• Developmental problems, with a focus on the response of parents, families and caregivers to the diagnosis and ongoing care of the child with special needs.
• Pervasive developmental disorders.
• General learning disability — the behaviour problems that arise secondary to this condition.
• Chronic illness — behavioural and psychological problems resulting from chronic illness, and parent and family difficulties resulting from chronic conditions, such as diabetes, epilepsy, chronic arthritis, chronic respiratory disease, physical disability and childhood cancer.
• Common behavioural paediatric problems such as enuresis, encopresis, sleep disturbance, eating difficulties, attention deficit and hyperactivity disorder, conduct disorder, anxiety, depression, and pre-school behavioural adjustment disorders.

You're to provide a summary of the issues involved in each case and how they were managed. Copies of clinical letters are not appropriate.

Cases will generally accumulate over a 2-year period and each case record must be signed by the supervisor.

Advanced Training Developmental and Psychosocial Training Supervisor's Report form (DOC) Psychosocial Logbook example (PDF) Psychosocial Logbook template   (DOC)

1 x 3-month period of training during your Basic or Advanced Training

Trainees must nominate a paediatrician with a special interest and skill in behavioural paediatrics or, where available, a child psychiatrist or paediatric clinical psychologist, to act as their supervisor.

We will provide your nominated supervisor with information about the requirements for the logbook as well as review the logbook.

A satisfactory Supervisor’s Report for Developmental and Psychosocial Training is required for your training to be certified.

Advanced Trainees who want their Developmental and Psychosocial Training rotation to count towards their specialty training time must also submit a specialty Supervisor’s Report.

Advanced Training Developmental and Psychosocial Training Supervisor's Report (PDF) Psychosocial Logbook example (PDF) Psychosocial Logbook template (DOC)

Haematology Research Project

Requirement for trainees who commenced before 2017.

The Haematology Research Project enables you to gain a broad range of knowledge as outlined in the Haematology Advanced Training Curriculum   (PDF) .

These requirements enable you to gain experience:

• in research methods
• in interpretation of research literature
• in participation in research at some stage of your career
• to develop quality improvement skills

Your research project should demonstrate:

• evidence of the skills of considering and defining research problems

Your research project must be marked as ‘satisfactory’ in order for you to complete Advanced Training. We recommend that trainees submit their research project by the submission date in their penultimate year of training to allow time for marking and resubmission of a project if it's initially marked ‘resubmit’.

Haematology Research Project cover sheet (DOC) RACP Online Learning Resources: Research Projects Research Project Checklist and Planner   (XLS)

1 x Haematology Research Project

Australia: 15 September.

Aotearoa New Zealand: 31 October.

Submit your research project by the due date in any year before the end of your Advanced Training.

Haematology Research Project cover sheet (DOC)

Your Haematology Research Project is a major requirement for your physician training and should be of an appropriate standard.

A research project is assessed on scientific merit and on its unique and honest intellectual content. Your research project must have direct relevance to the practice of clinical haematology.

Accepted formats

• A thesis or project prepared for a higher degree, such as a PhD or MD
• Clinical research
• Quality assurance undertaken in the final year of Advanced Training

Your Haematology Research Project must be presented in a standard suitable for publication and adhere to the norms of scientific writing with:

• defined aims
• well-articulated objectives
• prospectively defined methodology
• discussion that contextualises the work in line with current literature
• conclusions that relate to the aims

The research project needs to be written in sound English and free from grammatical and typographical errors. Vancouver referencing must be used.

Proofread your project before you present it to your supervisor for submission.

Review checklist

Your supervisor will review your submission for these items:

• Introduction
• Reference list
• Generic drug names written in lower cases
• Proprietary drug names written in upper cases
• Medicine doses written in standard units
• Vancouver referencing used
• Spelling/grammar check

Submit your Haematology Research Project, along with a signed research project cover sheet (DOC) , to [email protected] (Australia) or [email protected] (Aotearoa New Zealand).

The role of your project supervisor is to assist you in your project selection and design and provide guidance in your completion of the research project. Your project supervisor is not a joint author.

Your project supervisor is to certify that your research project is ready for submission via the research project cover sheet (DOC) .

You must allow adequate time for your project supervisor to review, provide feedback prior to completion and to certify for submission.

A Learning Needs Analysis (LNA) embeds the process of planning and evaluating learning in the trainee’s practice.

The LNA is designed to help you:

• tailor your learning experiences and build on clinical knowledge and skills
• enhance face-to-face communication with your supervisor
• provide information on your learning needs and progress
• reflect on your strengths, limitations and future learning strategies

Your ward/service consultant or supervisor are responsible for:

• advising you of available learning opportunities and resources
• ensuring you have set appropriate goals and identified achievable learning objectives
• reviewing your completed LNA and providing you feedback

Step-by-step: Learning Need Analysis

You need to complete a specified number of LNAs each year, per rotation. Refer to the training program requirements for the required number.

Prepare for your LNA

To plan the learning objectives for each training period, discuss the learning opportunities and resources available with your ward/service consultant or supervisor.

• career goals
• personal strengths and weaknesses
• strengths and constraints of the training site/rotation, including the expertise of the medical staff and the resources available
• requirements established in the curriculum, the Professional Practice Framework  and Professional Standards (PDF)

Create your LNA: Part 1

• Log into your online training portal and create a new LNA Basic Training Portal * | Advanced Training Portal  | AFOEM Portal  | AFRM Portal
• learning goals for the training period
• self-evaluation on current competency for the goals identified
• learning objectives from the curricula that map to your goals (optional)
• strategies and resources that will assist your learning
• contact details of additional supervisors (optional)
• Submit Part 1 of your LNA
• You and your consultant/supervisor can meet to review and improve your LNA
• Begin implementing your LNA over your training period

Complete your LNA: Part 2

At the end of your training period, you'll complete a self-evaluation of your LNA.

• Login to your online portal and open Part 2 of your LNA
• competency in the areas specified in the learning plan
• evidence of learning
• reflection on training period
• Complete your LNA by submitting LNA Part 2
• Your consultant/supervisor can access your completed LNA

2 x Learning Needs Analysis (LNA) each training year (1 per 6-month period), early in the rotation

Australia: 31 January in the following year

Aotearoa New Zealand: Due at the end of each rotation

In your final year, LNAs are due 15 October.

Submit your LNA via the Advanced Training Portal .

The Mini-Clinical Evaluation Exercise (Mini-CEX) is a formative assessment for trainees to receive timely, structured feedback on their performance in real clinical situations.

A Mini-CEX aims to:

• evaluate your clinical performance in a real-life setting
• guide your learning and improve clinical performance through structured feedback from an assessor
• identify ways for you to improve your practice in areas such as communication, history taking, physical examination and professional practice

Areas of assessment

You must complete encounters on a range of cases, each focusing on specific parts of the clinical encounter:

• History taking
• Medical interviewing skills
• Physical examination skills
• Professional qualities
• Counselling skills
• Clinical judgement
• Organisation and efficiency

Step-by-step: Mini-Clinical Evaluation Exercise

You need to complete a specified number of Mini-CEXs each year to meet the program requirements. Refer to the Mini-CEX requirements for the specified number per training year.

• Arrange a Mini-CEX with your assessor – discuss and agree on curriculum areas that require focus and your assessor will then choose an appropriate consultation.
• Provide your assessor a Mini-CEX rating form: Basic Training (PDF) | Advanced Training (PDF) | AFOEM (PDF)
• Undertake a patient consultation while being observed by your assessor – allow for 15 to 20 minutes.
• Your assessor will complete the Mini-CEX rating form and provide you with feedback – allow for 10 to 15 minutes.
• Once you have received feedback, both you and your assessor sign the rating form.
• Enter data from your completed Mini-CEX rating form into the online Mini-CEX tool in your training portal. Basic Training Portal Advanced Training Portal AFOEM Portal AFPHM Portal AFRM Portal
• Submit a copy of your completed form to your assessor using the online Mini-CEX tool.

2 x Mini-Clinical Evaluation Exercises (Mini-CEX) to be completed each training year (1 per 6-month period)

In your final year, Mini-CEXs are due 15 October.

Submit your Mini-CEX via the Advanced Training Portal .

Mini-Clinical Evaluation Exercise rating form (PDF)

Paediatric Advanced Life Support course

Requirement for aotearoa new zealand paediatrics & child health trainees only.

A Paediatric Advanced Life Support (PALS) course or equivalent ensures that you have the skills to support patients requiring resuscitation.

If you have completed a PALS course within 12 months prior to entering Advanced Training, you can submit your course certification.

We do not endorse any PALS course providers.

1 x Paediatric Advanced Life Support (PALS) course or equivalent, before the end of your Advanced Training

Submit a certified copy of your PALS certificate before completing Advanced Training.

We recommend you complete a PALS course within your first year of Advanced Training.

Supervisor's Report

A Supervisor's Report provides a comprehensive overview of your progress and achievement during the training year. It provides you with structured feedback on your performance from your supervisor and will inform the decision on the certification of your training.

Online Supervisor’s Report pilot

We have been looking at ways to improve reporting by offering online Advanced Training Supervisor’s Reports. We are extending our pilot, which commenced last year.

We ask that trainees and supervisors give the online report a go, save time by completing it online and share your feedback with us.

Learn more about the online Supervisor's Report pilot .

Note: Paper reports will continue to be available during the pilot.

Step-by-step: Online Supervisor’s Report

Your nominated supervisor(s) are listed in your online Supervisor’s Report and must complete their section of the report.

• Using a laptop or desktop PC, open a new Microsoft Edge or Google Chrome browser.
• Log in to your online Supervisor’s Report  using your RACP ID and multi-factor authentication .
• Open the report for your current training period.
• Complete the active fields in each report tab. Some fields are for supervisors only and will appear inactive to trainees.
• After your supervisor(s) have completed their assessment, you should meet with them to discuss their assessment of your performance.
• Following your discussion, your supervisor submits the report.
• You and your supervisor(s) can add comments and complete declarations in the ‘Submit report’ tab.

Your report is complete only after you and your supervisor(s) have completed the declarations.

Step-by-step: Paper Supervisor’s Report

All your nominated supervisors must complete the Supervisor’s Report. You can view your nominated supervisors by logging in to your training portal. Advanced Training  | AFRM

• Arrange a meeting to discuss and complete the Supervisor's Report with your supervisor(s).
• Check that you have completed all relevant sections of the report prior to submission as incomplete reports will be returned to you.
• Submit your report(s) in PDF (preferred) or Word format via email to your specialty, copying in:
• all supervisors
• your other specialty, if you’re actively dual training.
• Save a copy of your report(s) for your own records.

If you have more than 2 nominated supervisors, additional supervisors must complete either a Supplementary Supervisor Comments Report (DOC) or a separate Supervisor’s Report.

Dual trainees: Complete a Supervisor’s Report for the specialty most relevant to that training period. Separate reports for the same training period aren’t required for dual training.

Late submission

The Training Committee may not certify training if your Supervisor’s Report is submitted after the specified deadline.

Late reports will not be accepted unless you’ve been granted an extension through an Application for Special Consideration * (DOC) .

Special Consideration must be applied for prior to the Supervisor’s Report deadline. You can also submit a letter of explanation to support your application.

Applications will be assessed against the criteria outlined in the Special Consideration for Assessment Policy (PDF) .

Online Supervisor's Report Multi-factor authentication Education policies

12-month position (full-time and part-time trainees)

• 1 x Supervisor’s Report for the first 6 months of the training year due by 15 July
• 1 x Supervisor’s Report for the last 6 months of the training year due by 31 January in the following year

6-month position or less (separate supervisors or separate sites)

• Due 15 July for rotations in the first half of the year
• Due 31 January for rotations in the second half of the year

In your final clinical training year, we recommend submitting your last Supervisor's Report before the 31 January deadline to avoid delaying certification of the training period.

• 1 x Supervisor’s Report for the first 6 months of the training year due by 30 June
• 1 x Supervisor’s Report for the whole 12 months of the training year due by 15 December
• Due 30 June for rotations in the first half of the year
• Due 15 December for rotations in the second half of the year

If your supervisor hasn’t directly supervised you throughout the whole rotation, your supervisor should obtain individual reports from those who have and submit a composite report.

You are to ensure all supervisors receive a copy of the Supervisor’s Report. Previous copies of Supervisor’s Reports must be provided to your next supervisor.

Clinical Haematology online Supervisor's Report (RACP login required) Online Supervisor's Report FAQs Clinical Haematology Supervisor's Report (DOC) Supplementary Supervisor Comments Report   (DOC) Supervisor Details Amendment Form   (DOC)

Education policies RACP Online Learning resources Trainee support

Haematology Advanced Training Curriculum (PDF) Professional Qualities Curriculum   (PDF)

Forms and reports

Advanced Training Research Project cover sheet (DOC) Advanced Training Research Project marking criteria   (DOC) Advanced Training Research Project exemption form   (DOC) Research Project checklist and planner (XLS)

Case-based Discussion rating form   (PDF)

Developmental and Psychosocial Training Supervisor's Report (DOC) Psychosocial Logbook template (DOC) | Aotearoa NZ Psychosocial Logbook example (PDF) | Aotearoa NZ

Haematology Research Project cover sheet (DOC) Research Project checklist and planner (XLS)

Clinical Haematology online Supervisor's Report (RACP login required) Clinical Haematology Supervisor's Report (DOC) Online Supervisor's Report FAQs Supplementary Supervisor Comments Report (DOC) Supervisor Details Amendment Form (DOC)

Specialty societies

Haematology society of australia and new zealand.

The Haematology Society of Australia and New Zealand is the peak professional body representing clinical haematology physicians and paediatricians in Australia and Aotearoa New Zealand.

Australian and New Zealand Society of Blood Transfusion

The Australian and New Zealand Society of Blood Transfusion is comprised of members from various scientific, technical and medical backgrounds that are working within the areas of blood transfusion and transfusion medicine within Australia and Aotearoa New Zealand.

Australasian Society of Thrombosis and Haemostasis

The Australasian Society of Thrombosis and Haemostasis represents nearly 300 clinicians and scientists committed to promoting and fostering the acquisition and diffusion of knowledge and ideas relating to normal and abnormal haemostasis.

RACP resources

Trainee support is available through the Training Support Pathway, assisting you in navigating the progression through training process and reporting on your progress to your training committee.

RACP Online learning resources is home to all online learning opportunities for trainees, with its range of online learning courses, resources and interactive learning content. It also hosts:

• College Learning Series is an interactive online resource specifically targeted to the needs of Basic Trainees.
• Curated collections are learning resource guides based on the contributions and peer review of RACP Fellows and other experts.

Pomegranate Health podcast is a monthly medical podcast created by physicians, for physicians.

Evolve is a physician-led initiative to ensure the highest quality patient care through the identification and reduction of low-value practices and interventions.

© 2024 - Royal Australasian College of Physicians (RACP)  |  ABN 90 270 343 237 and ACN 000 039 047.

• Accessibility

• Call Monash Health
• See all locations
• Emergency departments
• Our hospitals and locations

Haematology

Monash haematology is a dynamic academic research organisation that integrates the best evidence-base into routine patient care..

We provide haematology care to a population of approximately 1.3 million, making it one of the largest services in Australia.

Our mission is to improve the health and well-being of patients with blood disease by providing the best care to every patient through integrated clinical practice, education, and research.

Key leadership areas in clinical care and research include:

• Lymphoma and Chronic Lymphocytic Leukaemia
• Acute Leukaemia and Myelodysplastic Syndromes
• Venous thromboembolic disease
• Haemoglobinopathy
• Obstetric Haematology
• Transfusion medicine

The unit is actively involved in exploring new models of healthcare delivery, the development of personalised diagnostics, and developing the next generation of cellular therapies for malignant blood disease.

We are responsible for training our future workforce through the integration of our clinical services with teaching and academia.

The unit has an international reputation for clinical research and has a large trial portfolio including several first-in-human, investigator-initiated and cooperative trial group studies. Monash Haematology researchers are key players in several national and international clinical registries and are actively involved in service optimisation through clinical audit.

We are active collaborators with several research organisations including School of Clinical Sciences at Monash Health (Monash University), the Australasian Leukaemia and Lymphoma Group, and the Children’s Oncology Group.

Through our partnership with Monash University, we have an emerging basic science and translational research programme embedded within the state-of-the-art Monash Health Translational facility.

Cellular Therapies

Blood cancer treatment is poised to enter a new and exciting era, heralded by the advent of potent and precise immune therapies. Cellular Therapy is a term used to describe human cells based treatment to replace or repair damaged tissue and/or cells.

In 2022, Monash Haematology is excited to be able to offer some of these cellular therapies as a part of our service.

Autologous haematopoietic stem cell transplantation

This is one of the most established forms of cellular therapies and is used to treat a variety of haematological conditions. In autologous stem cell transplant (ASCT), the patient’s own bone marrow stem cells are collected and reinfused after killing tumour cells with high dose chemotherapy. ASCT is offered to potentially cure several lymphoma in relapsed setting and as a front line therapy in multiple myeloma and mantle cell lymphoma.

CAR-T therapy (chimeric antigen receptor T cells)

CAR-T cell therapy is the latest form of cellular therapies. This involves genetic modification of immune cells (specifically T lymphocytes) to recognise and kill resistant cancer cells.

Autologous (patient’s own) CAR-T cell therapy is now approved to treat adult aggressive B cell lymphoma and B-cell acute lymphoblastic leukaemia in children and young adults. CAR-T cell therapy in other blood cancers including multiple myeloma as well as allogeneic (donor-driven) CAR-T cell therapy is also available in clinical trials.

Currently, Monash Haematology is working towards offering clinical trial CAR-T cell therapies. In the near future, we anticipate these therapies will become available as standard of care at Monash Health.

Our Haematology team

Director of Clinical Haematology: Professor Stephen Opat

Director of Laboratory Haematology: Associate Professor Sanjeev D Chunilal

• Professor Jake Shortt
• Dr Gareth Gregory
• Dr Pasquale Fedele
• Dr Olga Motorna
• Dr Danielle Oh
• Dr Charithani Keragala
• Dr Paul Yeh
• Dr Ashwini Bennett
• Professor Erica Wood
• Dr Allison Mo
• Dr Jasmine Singh
• Dr Agnes Yuen
• Dr Daniel Wong
• Dr Hannah Stevens
• Dr Shaun Fleming
• Dr Michael Low
• Dr Shahla Vilcassim
• Dr Susan Brown
• Donna Gairns

• Help & FAQ

View Scopus Profile

• ADJUNCT PROFESSOR (RESEARCH) , Australian Centre for Blood Diseases

Accepting PhD Students

PhD projects

Developing novel immunotherapeutic approaches to target TP53

Research activity per year

Personal profile

Professor Andrew Wei (MB,BS, PhD) is a clinical haematologist [MBBS 1993, FRACP 2002 (Haematology)], haematopathologist [FRCPA 2002], current National Health and Medical Research Council (NHMRC) clinical fellow, fellow of the Australian Academy of Health and Medical Sciences and specialist in acute myeloid leukaemia and myelodysplastic syndromes at the Peter MacCallum Centre and the Royal Melbourne Hospital in Melbourne, Australia. Dr Wei holds a joint appointment as the Metcalf Family Fellow and laboratory head in the division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute of Medical Research, where his laboratory has studied novel venetoclax combinations and mechanisms of resistance to BH3-mimetic drugs in acute myeloid leukaemia. He received his MB,BS degrees from the University of Melbourne and completed PhD studies at the Walter and Eliza Hall Institute for Medical Research investigating apoptosis in blood cancers. Professor Wei has served as chair of the acute leukaemia and myelodysplastic syndrome working party for the Australasian Leukaemia & Lymphoma Group since 2009. His current interest is focussed on developing novel clinical trials, particularly for patients with TP53 mutation and to target measurable residual disease (MRD) to prevent relapsing disease. Dr Wei has continuously mentored clinical fellows to develop AML trials for over a decade and has served on the European LeukemiaNet AML committee and editorial boards of Blood and the Journal of Clinical Oncology.

Research interests

Dr. Wei's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei's laboratory seeks to identify new therapeutic targets in leukaemia.

• Developing models of TP53 mutated AML
• Understanding the molecular mechanisms of evolution to TP53 mutated AML
• Developing novel therapies to target TP53 mutant leukemias

Monash teaching commitment

2022 - Present : Professor of Hematology- University of Melbourne

Clinical activities

Investigator initiated AML trial funding:

• Phase 1 study of RAD001 and low dose ara-C for elderly AML
• Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
• Phase 1 study of azacitidine and everolimus in relapsed AML
• Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
• Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML 
• Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML

Cooperative Group Studies Local Site PI:

• Phase 3 study: ALLG AML M12 study
• Phase 2 study: ALLG APML M4 study
• Phase 2/3: UK MRC16 AML study

Company sponsored studies as local site PI:

• Phase 2 study: CEP-701 in relapsed AML
• Phase 2 study: AS1411 in relapsed AML
• Phase 2 study: Midostaurin in systemic mastocytosis
• Phase 2/3 study: AZD1152 in older AML
• Phase 3 study: PKC412 in AML
• Phase 3 study: Amonafide in secondary AML
• Phase 3 study: Elacytarabine in relapsed AML
• Phase 3: Voreloxin in relapsed AML
• Phase 1: KB004 in advanced haematological malignancies
• Phase 1: Meisoindigo in AML unfit for chemotherapy

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

External positions

Co-stream lead Acute Leukaemia and Myelodysplastic Syndromes, Peter MacCallum Cancer Centre

1 Feb 2022 → …

Laboratory Head, Walter and Eliza Hall Institute of Medical Research (WEHI)

Research area keywords

• Acute myeloid leukaemia
• clinical trials

Collaborations and top research areas from the last five years

Dive into details.

Select a country/territory to view shared publications and projects

• 31 Finished

Projects per year

A Phase 1b/2, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects with Acute Myeloid Leukemia (AML)

Wei, A. & Kennedy, N.

9/09/21 → 31/12/25

Project : Research

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia

Wei, A. , Hodges, G., Purtill, D., Bennett, S., Hiwase, D. K., Tate, C., Enjeti, A., Bhattacharyya, A. & Tan, P.

31/08/21 → 31/12/24

INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial

Wei, A. , DiNardo, C., Roberts, A. W., Daver, N., Reynolds, J. , Blombery, P. A., Marlton, P. & Curtis, D.

1/07/21 → 30/06/25

A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

Wei, A. , Kennedy, N., Bajel, A. & Flemming, S.

2/12/20 → 31/12/25

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukaemia.

Flemming, S., Wei, A. , Bajel, A. & Kennedy, N.

20/10/20 → 31/12/25

Research output

• 104 Article
• 10 Review Article
• 8 Meeting Abstract
• 8 Comment / Debate
• 2 Editorial

Research output per year

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Research output : Contribution to journal › Article › Research › peer-review

C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.

Research output : Contribution to journal › Letter › Research › peer-review

Is BCL-xL the Achilles' heel of AEL and AMKL?

Research output : Contribution to journal › Editorial › Other › peer-review

Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells

2003: albert baikie award, best oral abstract presentation, haematology society of australia.

Wei, Andrew (Recipient), 2004

Prize : Prize (including medals and awards)

2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart

Wei, Andrew (Recipient), 2003

2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra

• 8 Membership of an advisory panel/policy group/ board

Activities per year

The Royal Australasian College of Physicians (External organisation)

Andrew Wei (Member)

Activity : Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board

Royal College of Pathologists of Australasia (External organisation)

Thrombosis and haemostasis society of australia and new zealand (thanz) (external organisation), haematology society of australia and new zealand (hsanz) (external organisation), european hematology association (external organisation).

Andrew Roberts, AM Profile page

• Theme Leader Blood Cells and Blood Cancer
• [email protected]
• featured news
• https://www.wehi.edu.au/laboratory/roberts-lab/
• External collaboration network

I am an Clinical Haematologist practising clinical medicine at the Royal Melbourne Hospital / Peter MacCallum Cancer Centre and leading translational research at WEHI and the University of Melbourne. As well as leading a research laboratory, I jointly lead WEHI’s Cancer Research and Treatments theme. I am also a clinical haematologist at The Royal Melbourne Hospital and Peter MacCallum Cancer Centre. After training in haematology in Brisbane, I did my PhD with Professor Donald Metcalf at WEHI, then a post-doc with Dr David Williams in the USA before returning to WEHI and The Royal Melbourne Hospital. I have been an academic leader in the clinical development of the novel targeted anti-cancer drug, venetoclax, from concept through preclinical development and clinical trials to registration. Currently I serve as Deputy Editor of Blood, the most cited journal in haematology. My long-term research interests are the development of new treatments for haematological malignancies, focussing especially on those blood cancers that are currently incurable. My lab collaborates closely with the clinical and laboratory researchers across the Victorian Comprehensive Cancer Centre, and with translational research colleagues at WEHI, especially my long term collaborator Professor David Huang. Major focuses of our research include: - Molecular basis of leukemogenesis and lymphomagenesis - Molecular basis of resistance to chemotherapy and targeted therapies - BCL-2 inhibitors and BH3 mimetics - Clinical trials of novel therapies

THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (WEHI) APPOINTMENTS

• Theme Leader, Cancer Research and Treatments Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia Nov 2018 - present
• Head of Clinical Translation Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 2010 - 2018
• Laboratory Head Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 2005 - present

ACADEMIC POSITIONS

• Clinical Haematologist The Royal Melbourne Hospital, Department Clinical Haematology, Australia Aug 2016 - present
• Clinical Haematologist Peter MacCallum Cancer Centre, Department Clinical Haematology, Australia Aug 2016 - present
• Clinical Haematologist The Royal Melbourne Hospital, Department of Clinical Haematology and Bone Marrow Transplant, Australia Oct 1998 - Jul 2016
• Metcalf Chair of Leukaemia Research The University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Australia 1 Jul 2013 - present
• Doctor of Philosophy (PhD) University of Melbourne, Australia 1997
• Bachelor of Medicine, Bachelor of Surgery University of Queensland, Australia 1984

CERTIFICATIONS

• FRACP Royal Australasian College of Physicians, Sydney, Australia 1993 - present
• FRCPA Royal College of Pathologists of Australasia, Sydney, Australia 1993 - present
• Cancer Research and Treatments

RESEARCH AREAS

• Personalised medicine
• Signal transduction

SKILLS AND EXPERTISE

• Clinical trials
• Drug discovery
• Single cell biology

BY RESEARCHER TYPE

• Scientific Leaders

DISEASE FOCUS

A NSW Government website

• Our Organisation
• Working with us
• Donations & Support

Institute of Haematology Research

The Royal Prince Alfred Institute of Haematology research unit performs high quality research in both clinical medicine and laboratory studies. We operate an expanding clinical trials unit with a growing trial portfolio which provides new treatment options that would otherwise be not accessible to members of our community. We have a large laboratory research program with major interests in immunotherapy, multiple myeloma, molecular diagnostics and coagulation disorders. The commitment to both clinical and laboratory research promotes excellence in our staff, and drives better outcomes and experiences for our patients and their families.

Our Key Research Themes

Our clinical trials unit continues to grow with a wide portfolio of trials covering both malignant and non-malignant haematology. We lead early phase clinical trials through to randomised controlled studies. We currently lead a diverse range of clinical trials in haematologic malignancies, including multiple myeloma, non-Hodgkin lymphoma, acute lymphoblastic leukaemia, acute myeloid leukaemia and myeloproliferative neoplasms. In addition we perform clinical trials for red cell disorders, haemophilia and thrombosis.

Professor Ho has continued to lead the RPA clinical trials unit and attract the most promising trials for our patients with Multiple Myeloma. We have been a major recruiting site for the PERSEUS study which is defining the new state-of-the-art induction therapy for Multiple Myeloma, by incorporating antibody therapy up-front into a potent induction combination. For patients with relapsed Myeloma we have trialled a new monoclonal antibody therapy (Belantamab-Mafodotin) in combination with Bortezomib (DREAMM7 study), and a new oral anti-Myeloma agent with high activity (CC-92480). 

One of the most exciting developments in Myeloma has the development of a potent BCMA-targeted CAR-T, named Ciltacaptagene. This agent has shown extremely high activity in patients with multiply relapsed Myeloma and no available therapeutic options (CARTITUDE2). We have trialled this agent earlier in the disease course of Multiple Myeloma patients, after 1-3 prior lines of therapy, in a phase three randomised trial (CARTITUDE4). This trial is ongoing but has completed recruitment and is likely to define a new standard-of-care for relapsed Myeloma. We have subsequently commenced CARTITUDE5, a trial testing the activity of Ciltacaptagene up front in patients with Myeloma; the results are expected to be paradigm shifting. 

Another immunotherapy agent which is showing great promise is Cevostamab, a bi-specific T cell engaging antibody. We are commencing enrolment in an early-phase study to assess this agent currently, and it will offer another avenue for our patients to harness the potential of the immune system to control Myeloma.  

RPA Haematology maintained its position as the major NSW site for CAR-T cell clinical studies. We have now treated 43 lymphoma and 5 acute lymphoblastic leukaemia patients.

We have also been key participants in Phase I allogeneic CAR-T trials, being one of only 2 Australian sites in allogeneic CAR-T cells manufactured by CRISPR-Cas9 technology directed against CD19, BCMA and CD70, utilised in diffuse large B cell lymphoma, acute lymphoblastic leukemia, myeloma and T cell lymphoma respectively.  Several patients have been treated and the trials are continuing.

In addition, we have attracted a novel cell therapy trial (NKARTA) utilising allogeneic engineered CAR-bearing NK cells for patients with a wide range of B cell non-hodgkin lymphoma subtypes. Early results have been released and demonstrate high activity with minimal toxicity.

In 2021 we continued to collaborate in the AGILE international multicentre phase III trial of Azacitidine ± Ivosidenib for patients diagnosed with Acute Myeloid Leukaemia (AML) with an IDH1 mutation. The significant benefit to patients treated with Azacitidine and Ivosidenib led to early closure of the trial and the results were published in the New England Journal of Medicine. We are also participating in two International phase III collaborative trials between the Australasian Leukaemia and Lymphoma Group (ALLG), German AML study group and Dutch HOVON group; the  AML-M23 and AML M-24 trials for the treatment of patients with newly diagnosed AML with an IDH or Flt3 mutation respectively, who are eligible for intensive chemotherapy and targeted therapy. Finally, we also participate in the ALL AML-M25 trials for elderly patients unfit for intensive chemotherapy but who may benefit from treatment with Venetoclax in combination with low dose cytarabine and pre-emptive Flt3 inhibition versus standard of care. There trials allow local patients to access new treatment options with the goal of improving survival.

The Institute of Haematology has been active in clinical and laboratory research in acute promyelocytic leukaemia (APL) for over 20 years. That program, led by Prof Harry Iland, culminated in major publications of the ALLG APML3 and practice-changing ALLG APML4 trials. Participation in the ALLG APML5 trial has continued during 2020-2021. Prof Harry Iland is the principal Investigator for this investigator-initiated phase I pharmacokinetic study of a novel oral formulation of arsenic trioxide (ATO) for use in patients with acute promyelocytic leukaemia (APL). National accrual was completed during 2020, and the last patient completed ATO and ATRA consolidation in January 2021. Results of part 1 of the study were presented at EHA in 2019, and the part 2 data which conformed bioequivalence with the intravenous formulation were presented at EHA in 2021. Statistical analysis is ongoing prior to manuscript submission in 2022. It is anticipated that the availability of an oral formulation of ATO for routine clinical use will significantly reduce utilisation of hospital resources and improve the overall treatment experience of patients with APL. Prof Iland is internationally recognised for his contributions to APL, and is a member of the European LeukemiaNet panel of experts that published updated diagnostic and treatment guidelines for APL in 2019. He has also collaborated with international APL experts on a retrospective analysis of the impact of cytogenetic abnormalities in APL patients treated with ATO-based regimens (accepted for publication in Blood Advances). Together with colleagues from the UK, North America and Australia, he is continuing a retrospective review of APL patients who present with extreme levels of white blood cell elevation, and a further study of the role of obesity in the frequency and severity of ATO-associated peripheral neuropathy during APL therapy. 

Our bone marrow transplant group is led by Associate Professor Stephen Larsen. Our unit is a major contributor to both national and international registries. In addition to ongoing accreditation by the Australian Blood and Marrow Donor Registry (ABMDR) and the Centre for International Blood and Marrow research (CIBMTR), our transplant service is the only NSW service accredited by the Therapeutic Good Administration (TGA). We have contributed to studies looking at the outcomes of patients receiving allogeneic bone marrow transplants in NSW, as well as the impact that COVID-19 has on transport of blood and bone marrow allografts into Australia. Our contribution has also included our experience with novel anti-fungal formations to prevent opportunistic infections in patients undergoing allogeneic bone marrow transplantation.

RPA is one of the leading centres for the treatment of Thalassemia and Sickle Cell Disease.

In thalassemia, RPA Haematology was the leader in Australian recruitment in the BELIEVE study of luspatercept, the beta-activin receptor which has been shown to increase erythropoiesis and haemoglobin levels in transfusion-dependent thalassemia. We are now conducting a trial in TMPRSS6 mRNA in thalassemia intermedia, investigating a novel mechanism to modulate erythropoiesis and iron metabolism. Prof Ho is chair of the Steering committee of the National haemoglobinopathies registry, in which Dr Anna Nelson, Haemoglobinopathy Fellow, was a key contributor to the Sickle Cell Disease Registry. Analysis is ongoing with plans for publication of results in 2021. Anna Nelson also presented her work in the Laboratory with Dr Freda Passam at the annual Blood conference.

The Thrombosis Service of Haematology RPA entered its 4th year of operation in 2021. The year 2021 saw NSW with a lengthy lockdown due to COVID19. Thrombosis specialists, Dr Scott Dunkley and Dr Freda Passam, reviewed over 1100 patients in the Thrombosis Clinic of RPA in the Charles Perkins Centre, the majority by telehealth. They also provided consultation to RPA Virtual Hospital and RPA inpatients for venous thromboembolism and COVID19-related thrombosis. 2021 was also the year of mass vaccination for COVID19 with the rollout of Astra Zeneca and Pfizer vaccine. This brought the unanticipated rare side effect of Astra Zeneca vaccine induced thrombosis thrombocytopenia (VITT). The Thrombosis team RPA provided extensive consultation on the risk of thrombosis and thrombocytopenia related to COVID19 vaccines. Dr Passam was a member of the THANZ Committee for VITT which developed national guidelines for the diagnosis and management of VITT. The Thrombosis team developed one of the 3 functional assays performed on a national scale for the diagnosis of VITT (Multiplate) and was one of the 2 centres in NSW to perform the immunological assay for the diagnosis of VITT. Three haematology advanced trainees and 3 USYD MD students undertook research projects in Thrombosis. MD student Ahmed Sultan presented oral presentations at Blood 2021. Haematology fellow Dr Caroline Dix and AT Dr Yvonne Kong received best poster awards at Blood 2021.  

The Haemophilia unit, under the leadership of Drs Scott Dunkley, Freda Passam and Liane Khoo care for over 500 patients with haemophilia and other rare inherited bleeding disorders as part of the Comprehensive Haemophilia Treatment Centre.  The Haemophilia centre has participated in clinical trials for new therapies for haemophilia, including gene therapy, non-factor replacement (siRNA and antibody) and ultra-long acting FVIII, bringing cutting edge therapies to local patients. 

In collaboration with Professor Vivien Chen at Concord Hospital, senior scientist in-charge of coagulation, Mr Geoffrey Kershaw and Haematology Fellow, Dr Caroline Dix lead an Australia wide study on setting up a coagulation assay of Emicizumab, a new monoclonal antibody treatment that had revolutionised the treatment of Haemophilia A.

Our unit also undertakes supportive care research in haematology nursing. Tracy King myeloma CNC was recently awarded her PhD, exploring the symptoms and experiences of patients with myeloma taking corticosteroids as part of their treatment. Phase IV of Tracy's research is ongoing and was awarded a recent Cancer Services Research Grant by SLHD. This year, Tracy was awarded a Sydney Cancer Institute Seed Grant for $24,812 for her study 'Personalised care for older people with myeloma'.

Tracy King holds an affiliate position as Clinical Research Fellow with the Cancer Nursing Research Unit Sydney Nursing School where she collaborates with Prof Kate White and team on a range of other supportive care research projects. A summary of ongoing studies includes:

• Measurement properties of the Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM) in a multi-centre study with concurrent health related quality of life (HRQoL) measurement. Phase IV of a study, lead investigator Tracy King, to develop and evaluate a new Patient-Reported Outcome Measure to test the measure the impact of steroids associated with therapy for Myeloma. Recruiting at 4 NSW sites. 
• More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial. Tracy King and Professor Joy Ho hold CI positions on this grant and are currently progressing the project for a large national multi-centre study. This study was awarded a $1,678,493 MRFF Rare Diseases Unmet Need grant and builds on previous work undertaken by this group in past year. 
• A Spencer, C Rutherford, J Reynolds, J Ho, Z McQuilten, E Moore, T King, E Wood, J Harrison, A Irving. 
• Personalised care for older people with multiple myeloma. Awarded $24,812 Sydney Cancer Institute Seed Funding Grant April 2022. Tracy King is lead investigator and Dr Christian Bryant and Kristina Whelan are associate investigators. Protocol for study being finalised at timing of submission of this report. 
• 'Implementation of routine enhanced clinical screening for chemotherapy-induced peripheral neurotoxicity: a feasibility study. CIPN-Screen'. Study lead investigator A/Prof Susanna Park of Brain and Mind Centre Sydney University, Tracy King is an associate investigator on this study.  
• Lenalidomide/bortezomib/dexamethasone therapy: Evaluation of a NSW Harmonised Approach and Review of Toxicity and Outcomes. Study leads Dr Georgia McCaughan and Dr Adam Bryant. Tracy King, Joy Ho, Christian Bryant and Kristina Whelan are investigators on this study which aims to audit outcomes across sites in NSW. 
• Lead investigator Tracy King has commissioned a Nursing White Paper: Optimising Multiple Myeloma Services in NSW through the contribution of Myeloma Advanced Practice Nurses. Prof Kate White and the CNRU team have been engaged to undertake this work. The White Paper is undertaken on behalf of the NSW Myeloma Working Group with associate investigators Prof C Ward, E/Prof D Joshua, J Jagger (NP), J Sipavicius (NP). Findings to be presented at Blood (HSANZ Annual Scientific Meeting Nursing) September 2022 Sydney. 
• Myeloma Treatment Scheduler: Development of an online tool to create individual myeloma treatment schedules to be printed and provided to patients to aid understanding, improve adherence and enhance myeloma patient care. Myeloma Specialist Practice Network Haematology Society of Australia and New Zealand (HSANZ). T King, J Hempton, J Jagger, A Snowden, J Sipavicius, C Woodrow, S Haines.  Further protocols and additional of patient information resources added late 2021. Discussions with Myeloma UK to adapt for use in UK region. 

Under Prof Ho's direction our Myeloma Research laboratory has continued to develop its capacity for basic science and translation/diagnostic work. We have focused on molecular diagnostics, sensitive assessments of residual disease, and the greater understanding of the immune microenrviroment. 

We have also established a novel next-generation sequencing platform to define mutational load in malignant cells from Myeloma patients at diagnosis and with relapsed disease. This is currently undergoing validation and will provide the most refined prognostic tool currently available. 

We have set up a state-of-the-art platform (Euroflow) to monitor minimal residual disease (MRD) in Multiple Myeloma patients. This has established RPA as the only site in Australia on the Eastern seaboard with the capacity to assess Myeloma MRD with a validated assay. We have established a project to use this assay to assess level of Multiple Myeloma in peripheral blood samples collected early during the commencement of therapy. Initial data suggests that this will demonstrate which patients are destined to respond poorly early, so that changes to therapy can be made to improve outcomes. This is being performed as a collaborative project across 4 hospitals in NSW. 

We have also studied the immune system of Myeloma patients using Single Cell Next-Generation Sequencing, revealing the T cell compartment in the bone marrow in greater detail than seen before (manuscript in preparation). This will help us to understand how Myeloma evades immune control. 

The Institute of Haematology at RPA also has a number of laboratory studies into benign haematology. These include the novel characterisation of myeloid cells in patients with thalassaemia, defining the platelet proteome in type 2 diabetes mellitus and the evaluation of thrombophilia studies in patients with ischaemic strokes.

The ALLG is currently preparing to open an AML platform trial which will examine the role of novel combinations of targeted therapy guided by a comprehensive measurable residual disease (MRD) monitoring program. Prof Harry Iland is the chair of the MRD reference committee for the study which has the potential to dramatically change the way in which patients with AML are managed during remission.

The advent of next generation sequencing (massively parallel sequencing) has changed the diagnostic paradigm for patients with haematological malignancies. The Molecular Haematology laboratory at RPAH has conducted an extensive validation program of a myeloid gene panel with the goal of achieving NATA accreditation, and those activities supported the unit's participation in a joint ALLG / RCPAQAP initiative assessing candidate gene panel testing for AML which was published in Pathology. 

Selected Grants

Our publications.

In Sydney Local Health District, we acknowledge that we are living and working on Gadigal , Wangal and Bediagal land, part of the  EORA Nation . We pay our respect to all elders past, present and emerging. Our vision is to have the healthiest Aboriginal community in Australia.

© 2024 Sydney Local Health District, ABN 17 520 269 052  Accessibility   Disclaimer   Privacy

Prof Mark Polizzotto MB BS BMedSc PhD FRACP FRCPA

Clinical Haematologist

Session times.

Mark is a consultant haematologist with a commitment to providing expert, compassionate patient-centred care to diverse populations. He is Professor of Medicine at the Australian National University, where he leads the Clinical Hub for Interventional Research (CHOIR) and Senior Staff Specialist at the Canberra Hospital.

Mark trained in medicine at the University of Western Australia, and research honours at the Walter and Eliza Hall Institute, University of Melbourne. He completed his specialty training in internal medicine, clinical and laboratory haematology at St Vincent’s Hospital Melbourne and the Peter MacCallum Cancer Centre. He then completed further subspeciality training with a focus on immunotherapy for lymphoproliferative disorders and cancers of immunodeficiency at the National Cancer Institute, U.S. National Institutes of Health, along with a doctorate (PhD) through the University of Melbourne.

Mark is internationally recognised for his contributions to the field of haematology, having contributed to clinical guidelines and led multiple international clinical trials in immunotherapies and advised the Australian and other governments through expert panel memberships. He has a deep commitment to advancing care through research, with over 100 peer-reviewed publications in the leading international journals including Blood, Journal of Clinical Oncology, Lancet, Nature Medicine, and the New England Journal of Medicine.

Opening Hours

Monday to Friday 8.30 am to 5.00 pm

Please contact our office for the session times for individual specialists.

National Capital Medical Specialists Suite 3 Ground Floor National Capital Private Hospital Corner Gilmore Crescent and Hospital Road Garran, Canberra

Contact Details

Phone 02 6222 6607 Fax 02 6222 6663

Full contact details »

• Privacy Policy

© Copyright 2018 – 2020 National Capital Medical Specialists (NCMS), Canberra · Credits

• Footer navigation
• Art of Science
• Discovery tours
• Research Our research Finding better ways of detecting and treating a wide range of diseases, and helping our community to live long and healthy lives. Overview Diseases Areas of research Technologies Researchers and labs Collaborative centres Research facilities Clinical trials Business development and ventures
• About About WEHI Where the world’s brightest minds collaborate and innovate to make discoveries that will help us to live healthier for longer. About WEHI Contact us Our values Diversity and inclusion Reconciliation Our people Alumni Organisational structure History Awards Annual reports Strategic plan
• Careers and education Working and studying at WEHI WEHI promotes a scientific environment that emphasises innovation, collaboration and excellence. Careers Working at WEHI Scientific positions Professional positions Education Studying at WEHI PhD Honours Masters Undergraduate Clinician-scientist training Work experience Student research projects Student association Students in focus Learning Hub
• Support us +
• Ethics and integrity
• Terms of use
• Supplying to WEHI
• Feedback and complaints
• Students in focus

Help us live healthier and longer lives.

If you would like to give to a specific research program or support the work of a particular researcher, contact our fundraising team today.

• Researchers and labs

Prof Andrew Roberts

• [email protected]
• Personalised medicine
• Blood cancers

Technologies

• Drug discovery

Themes / Divisions

• Cancer Research and Treatments
• Blood Cells and Blood Cancer

Sections on this page

I am an Clinical Haematologist practising clinical medicine at the Royal Melbourne Hospital / Peter MacCallum Cancer Centre and leading translational research at WEHI and the University of Melbourne.

After training in haematology in Brisbane, I did my PhD with Professor Donald Metcalf at WEHI, then a post-doc with Dr David Williams in the USA before returning to WEHI and The Royal Melbourne Hospital.

I have been an academic leader in the clinical development of the novel targeted anti-cancer drug, venetoclax, from concept through preclinical development and clinical trials to registration. Currently I serve as Deputy Editor of Blood, the most cited journal in haematology.

My long-term research interests are the development of new treatments for haematological malignancies, focussing especially on those blood cancers that are currently incurable.. My lab collaborates closely with the clinical and laboratory researchers across the Victorian Comprehensive Cancer Centre, and with translational research colleagues at WEHI, especially my long term collaborator Professor David Huang.

Major focuses of our research include:

• molecular basis of leukemogenesis and lymphomagenesis
• molecular basis of resistance to chemotherapy and targeted therapies
• BCL-2 inhibitors and BH3 mimetics
• clinical trials of novel therapies

Australia, University of Queensland, MB BS, 1984 Australia, University of Melbourne, PhD, 1997

The Royal Melbourne Hospital Peter MacCallum Cancer Centre University of Melbourne

2020, Ramaciotti Medal for Excellence in Biomedical Research (with Seymour) 2019, Prime Ministers Prize for Innovation (with Huang, Lessene and Czabotar) 2018, Victoria Prize for Science and Innovation for Life Sciences, Victorian State Government (jointly with Seymour) 2018, Clunies Ross Knowledge Commercialisation Award, Australian Academy of Technology and Engineering (with Huang, Lessene and Czabotar) 2017, Eric Susman Prize, Royal Australasian College of Physicians 2016, Johnson & Johnson Eureka Prize for Innovation in Medical Research (with Huang, Lessene and Czabotar) 2016, Healthcare Innovation Award – Research, Melbourne Health (with Anderson, Huang, Seymour and Magee) 2015, Thomson Reuters Citation Award – Australia 2013, Metcalf Chair of Leukaemia Research, The University of Melbourne 2004, Burnet Prize, Walter and Eliza Hall Institute of Medical Research

2022-2026, NHMRC Synergy Grant 2011139 Understanding and averting blood cancer resistance to therapy (CIA) 2022-2024, MRFF Clinical Trials Activity 2015299 Eliminating HIV that persists on antiretroviral therapy through treatment with the BCL-2 antagonist, venetoclax (CIE) 2021-2025, NHMRC Clinical Trials and Cohort Studies Grant 2006403 INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial (CIC) 2020-2025, MRFF 1170100 The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma (CIB) 2020- 2024, National Health and Medical Research Council Investigator Grant 1174902 2020, Australian Cancer Research Foundation (infrastructure grant) ACRF Program for Resolving Cancer 2017-2022, Specialised Centre of Research, Molecular regulation of blood cell production and function Leukemia and Lymphoma Society (USA) 2017-2021, Program Grant 1016647: Molecular regulation of blood cell production and function, National Health and Medical Research Council

Director, Victorian Comprehensive Cancer Centre Alliance, 2022 – Member, WHO Expert Committee on the Selection and Use of Essential Medicines, 2021 Deputy Editor, Blood, 2020 – Chair, Life Saving Drugs Program (LSDP) Expert Panel, 2019 – Director, Australasian Leukaemia and Lymphoma Group (ALLG), 2010 – Scientific Program Co-Chair, American Society of Hematology (ASH) Annual Scientific Meeting, 2015 Chair, Cancer Council Victoria (CCV) Board, 2013-2017 (Member 2004 – 2018) Member, Australian Government Pharmaceutical Benefits Advisory Committee (PBAC), 2007 – 2018

Publications

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Enschede SH, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2016; 374(4):311-22. PMID: 26639348

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash L, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 2017; 18(2):230-240. PMID: 28089635

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio JD, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus venetoclax for the treatment of Mantle Cell Lymphoma. N Engl J Med 2018; 378(13):1211-1223. PMID: 29590547

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov 2019; 9(3):342-353. PMID: 30514704

Roberts AW, Wei AH, Huang DCS. BCL2 inhibitors and MCL1 inhibitors for hematological malignancies. Blood 2021;138(13):1120-1136. PMID: 34320168

Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, Jabbari JS, Peng H, Lew TE, Teh CE, Gouil Q, Georgiou A, Tan T, Djajawi TM, Tam CS, Seymour JF, Blombery P, Gray DHD, Majewski IJ, Ritchie ME*, Roberts AW*, Huang DCS*. Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy. Blood 2022 Nov 17;140(20):2127-2141. PMID: 35709339

Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DCS, Davids MS, Letai A, Roberts AW. The BCL2 Selective Inhibitor Venetoclax Induces Rapid Onset Apoptosis of CLL Cells in Patients via a TP53 Independent Mechanism. Blood 2016 Jun;127(25):3215-24 PMID: 27069256

Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, Khaw SL, Lessene G, Spencer A, Herold MJ, Roberts AW, Huang DC. Hierarchy for targeting pro-survival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 2016 128(14):1834-1844 PMID: 27465916

Stilgenbauer S, Eichorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Bottcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: a Pivotal Phase 2, Open Label, Multicenter Study. Lancet Oncol 2016; 17(6):768-78. PMID: 27178240

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 2017; 35(8):826-833. PMID: 28095146

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016; 538(7626):477-482. PMID: 27760111

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DCS, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang HC, Humerickhouse RA, Rosenberg SH, Elmore SW. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine. 2013 Feb;19(2):202-8. PMID: 23291630.

Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DCS, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology. 2012 Feb;30(5):488-96. PMID: 22184378.

Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC, Kile BT. Programmed anuclear cell death delimits platelet life span. Cell. 2007 Mar 23;128(6):1173-86. PMID: 17382885.

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006 Nov;10(5):389-99. PMID: 17097561.

Lab research projects

A series of clinical trials and translational research projects that are developing venetoclax and other BH3 mimetics as therapy for leukaemias, lymphoma and myeloma.

Definition of how cell lines, primary cells and samples from patients on clinical trials manifest innate and acquired resistance to BH3 mimetics.

Identification of key BCL2 family proteins in myeloma, and how to target them for therapy.

In collaboration with colleagues at WEHI, particularly Professors Andrew Wei and David Huang, and partner hospitals, we study serial samples from patients on standard and experimental therapies. Using the latest single cell-omics, we characterise the basis for resistance and design new strategies to circumvent this.

• News and features

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.

• Privacy Policy

By using this website, you agree to our use of cookies in accordance with our Privacy Policy and Terms of use .

Haematology@East

Dr Roya Shahidi

Dr Shahidi is a clinical and laboratory haematologist. She completed her training through Eastern Health in Melbourne and Tasmanian Health Services. She obtained her PhD at Melbourne University and is a fellow of both the Royal Australasian College of Physician (FRACP) and the Royal College of Pathologist of Australasia (FRCPA). She is interested in translational research in cancer genomics and targeted therapy. Her clinical interests include malignant and non-malignant haematology.

She is a member of the American Society of Hematology, Haematology Society of Australia and New Zealand, Australian Leukemia and Lymphoma Group and International Society for Laboratory Hematology.

Dr Shahidi sees patients with a wide range of haematological conditions (malignant and non-malignant). She offers a short waiting time for new patients. Dr Shahidi can consult in English and Persian/Farsi .

I moved to Hobart, and not accepting new referrals for patients in Melbourne

New referrals (for patients in Tasmania/Hobart) can be faxed to 03 6224 8992.

Melbourne Haematology

• Site Map Links
• About Melbourne Haematology
• Anticoagulation in Pregnancy
• Anticoagulation - Rivaroxaban (Xarelto®) or apixaban (Eliquis®)
• Antiphospholipid Syndrome
• Below Knee DVT
• Bone Marrow Biopsy
• Bone Marrow Biopsy - Post Procedure Instruction
• Chronic Lymphocytic Leukaemia (CLL)
• Chronic Myeloid Leukaemia (CML)
• DVT (deep venous thrombosis)
• Factor V Leiden Mutation
• Full Blood Count
• Haemochromatosis
• Hereditary Haemorrhagic Telangiectasia (HHT)
• Hereditary Spherocytosis
• Iron Deficiency Anaemia
• Iron Infusion with FCM
• ITP in Adults
• ITP in Children
• Lymphadenopathy
• Myelodysplastic Syndrome - MDS
• Neutropenia
• Peri-operative management of anticoagulation
• Post Thrombotic Syndrome (PTS)
• Prothrombin Gene Mutation
• Pulmonary Embolus (PE)
• Raised Serum Ferritin
• Superficial Thrombophlebitis
• Assoc Prof Ashish Bajel
• Assoc. Prof Chris Barnes
• Assoc Prof Philip Campbell
• Dr Duncan Carradice
• Dr Khai Li Chai
• Assoc. Prof Sanjeev Chunilal
• Dr Katherine Cummins
• Dr Pasquale Fedele
• Dr Shaun Fleming
• Dr Isaac Goncalves
• Dr Gareth Gregory
• Dr Simon He
• Dr Henry Januszewicz
• Dr Anna Kalff
• Dr Zane Kaplan
• Dr Sueh-li Lim
• Assoc Prof Michael Low
• Assoc Prof Kylie Mason
• Dr Ming Ong
• Professor Stephen Opat
• Professor Andrew Perkins
• Professor Hang Quach
• Dr Bill Renwick
• Professor Anthony Schwarer
• Dr Andre Simmance
• Professor Andrew Spencer
• Dr Maciej Tatarczuch
• Professor Huyen Tran
• Dr Paul Turner
• Dr Shahla Vilcassim
• Dr Hiu Lam Agnes Yuen
• What is a Haematologist?
• New Patient Form and Information
• Fatigue Severity Scale (FSS) - Questionnaire
• Contacts - Directory of Haematologists (2024)
• Haematology Reference Guides
• Skip to content

Melbourne Haematology - Clinical and Laboratory Consultant Haematologists

Our haematologists, patient fact sheets, for referrers, practice locations, melbourne haematology is a group of clinical and laboratory trained specialist haematologists based in melbourne dedicated to provide comprehensive management of patients with haematological disorders..

The haematologists within Melbourne Haematology have specialised expertise covering all areas of clinical and diagnostic haematology.

Use the links above to find out more about each of our haematologists, their practice locations and access comprehensive patient information resources about blood disorders, their diagnosis and management.

Haematological Disorders and Conditions

Clinical and laboratory trained haematologists are able to provide comprehensive management for patients with haematological disorders..

• Management of leukaemia and lymphoma
• Myeloproliferative disorders
• Myelodysplasia
• Multiple myeloma and paraproteinemias
• Anaemia, neutropenia and thrombocytopenia
• Cytopenias and other FBE abnormalities
• Elevated serum ferritin or iron overload Haemochromatosis
• Management of DVT or PE
• Assessment of bleeding or bruising
• Warfarin management
• Investigation of prothrombotic abnormalities Vitamin B12 / folate or iron deficiency
• Paediatric haematology
• Obstetric haematology
• Bone marrow failure disorders
• Haematological aspects of menorrhagia
• Haemoglobinopathy
• Diagnosis and management of Von Willebrand's disease
• Bone marrow examination service
• Autograft bone marrow transplant service
• Transfusion medicine

The New Frontier in Treating Cancer

Treating cancer: dr kylie mason comments on the new approaches to treating cancers such as leukaemia and non-hodgkins lymphoma ahead of national science week 2015.

This article appeared in the The Age, August 16, 2015 Author: Science Writer, Bridie Smith

Ask a medical researcher if we will ever find a cure for cancer and the answer will likely come cushioned with a gentle smile and shake of the tilted head before it's verbalised - no.

"It's an infinite number of diseases, it's not just one disease," says leukaemia researcher and scientist at the Royal Melbourne Hospital and Melbourne University Kylie Mason . "The more we know the more we realise what we don't know."

Progress, helped by advances in everything from supercomputing to immunotherapy and genomics, is nevertheless being made.

In Dr Mason's field alone, researchers have gone from believing that there were just two kinds of non-Hodgkin lymphoma to having identified more than 60 types. And that's not including the subtypes that have been documented.

According to the Cancer Council, the five-year survival rate for all cancers has improved from 47 per cent between 1982-87 to 67 per cent in 2007-11.

And there is more improvement to come, thanks to the advent of what is called personalised medicine which tailors treatment to the individual's profile, not the cancer.

"Every patient is an individual," said Dr Mason, who herself survived leukaemia as a teenager. "They are going to respond differently to somebody else with the same named diagnosis. We're not treating a cancer, we're treating a patient."

Dr Kylie Mason , MBBS PhD FRACP FRCPA is also a Clinical and Laboratory Haematologist at Melbourne Haematology.

More Articles...

• Qantas first airline in the world to introduce exercise video to help prevent DVT
• Leukaemia: When Blood Goes Bad

Our Haematologists

• Associate Professor Ashish Bajel
• Associate Professor Chris Barnes
• Associate Professor Philip Campbell
• Associate Professor Sanjeev Chunilal
• Dr James Griffiths
• Dr Simon Z. He
• Associate Professor Michael Low
• Associate Professor Kylie Mason

Latest Fact Sheets

More detail

Melbourne Haematology is a group of clinical and laboratory trained specialist haematologists based in Melbourne dedicated to provide comprehensive management of patients with haematological disorders

Patient Fact Sheets

• Anticoagulation - Being on long-term anticoagulation medication rivaroxaban (Xarelto®) or apixaban (Eliquis®)
• Iron Infusion with ferric carboxymaltose (FCM)

Find a Haematologist

Melbourne Haematology currently has over 30 Haematologists practicising in over 20 locations throughout Melbourne and surrounding suburbs including Geelong.

View Our Locations page to quickly find your nearest Haematologist.

2024 Haematologist Directory

DOWNLOAD OUR 2024 HAEMATOLOGIST DIRECTORY [VIEW PDF]

• Haematology Fact Sheets
• Haematologists
• For Patients
• For Referrers

Study at Cambridge

About the university, research at cambridge.

• Undergraduate courses
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Postgraduate events
• Fees and funding
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Term dates and calendars
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement
• Give to Cambridge
• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges & departments
• Email & phone search
• Museums & collections
• Course Directory

PhD in Haematology

Postgraduate Study

• Why Cambridge overview
• Chat with our students
• Cambridge explained overview
• The supervision system
• Student life overview
• In and around Cambridge
• Leisure activities
• Student unions
• Music awards
• Student support overview
• Mental health and wellbeing
• Disabled students
• Accommodation
• Language tuition
• Skills training
• Support for refugees
• Courses overview
• Department directory
• Qualification types
• Funded studentships
• Part-time study
• Research degrees
• Visiting students
• Finance overview
• Fees overview
• What is my fee status?
• Part-time fees
• Application fee
• Living costs
• Funding overview
• Funding search
• How to apply for funding
• University funding overview
• Research Councils (UKRI)
• External funding and loans overview
• Funding searches
• External scholarships
• Charities and the voluntary sector
• Funding for disabled students
• Widening participation in funding
• Colleges overview
• What is a College?
• Choosing a College
• Terms of Residence
• Applying overview
• Before you apply
• Entry requirements
• Application deadlines
• How do I apply? overview
• Application fee overview
• Application fee waiver
• Life Science courses
• Terms and conditions
• Continuing students
• Disabled applicants
• Supporting documents overview
• Academic documents
• Finance documents
• Evidence of competence in English
• Terms and Conditions
• Applicant portal and self-service
• After you apply overview
• Confirmation of admission
• Student registry
• Previous criminal convictions
• Deferring an application
• Updating your personal details
• Appeals and Complaints
• Widening participation
• Postgraduate admissions fraud
• International overview
• Immigration overview
• ATAS overview
• Applying for an ATAS certificate
• Current Cambridge students
• International qualifications
• Competence in English overview
• What tests are accepted?
• International events
• International student views overview
• Akhila’s story
• Alex’s story
• Huijie’s story
• Kelsey’s story
• Nilesh’s story
• Get in touch!
• Events overview
• Upcoming events
• Postgraduate Open Days overview
• Discover Cambridge: Master’s and PhD Study webinars
• Virtual tour
• Research Internships
• How we use participant data
• Postgraduate Newsletter

Primary tabs

• Overview (active tab)
• Requirements
• How To Apply

The Department of Haematology is located on the Cambridge Biomedical Campus. Research in the department falls into three main areas with major relevance for human disease: The Haematopoiesis and Blood Cancer Group, the Structural Medicine and Thrombosis Group, and the Transfusion Medicine Group.

Those Haematology research groups belonging to the Cambridge Stem Cell Institute ( https://www.stemcells.cam.ac.uk ) moved into a brand new purpose-built facility on the Cambridge Biomedical Campus in 2019. The other Haematology groups are based at the Cambridge Institute for Medical Research, the NHS Cambridge Blood Centre and the Sanger Institute. More information can be found  here .

The department offers this full-time or part-time PhD programme of research under the individual supervision of a principal investigator based in the Department of Haematology. A full list of Haematology Principal Investigators can be found on the departmental website .

PhD students on this course are based in a research group, supported by their primary supervisor and the Postgraduate Education Committee and Postgraduate Student Committee. There is no taught or examined course work, but students are encouraged to attend research seminars on the Biomedical Campus and elsewhere in the University.

Students write a thesis, which is examined via an oral examination.

We welcome applications from postgraduates wanting to work towards a PhD, in any of the labs belonging to the Department of Haematology. Successful applicants must meet the University's minimum academic admissions criteria, and applicants are required to contact potential supervisors before submitting an application, to discuss their application and funding possibilities. A list of Haematology Principal Investigators can be found on the Department of Haematology website .

Learning Outcomes

At the end of their PhD, students should:

• have a thorough knowledge of the literature and a comprehensive understanding of scientific methods and techniques applicable to their own research;
• be able to demonstrate originality in the application of knowledge, together with a practical understanding of how research and enquiry are used to create and interpret knowledge in their field;
• have developed the ability to critically evaluate current research and research techniques and methodologies;
• have self-direction and originality in tackling and solving problems;
• be able to act autonomously in the planning and implementation of research; and
• have gained oral presentation and scientific writing skills.

Those who wish to progress to a PhD after completing an MPhil will be required to satisfy their potential supervisor, Head of Department and the Faculty Degree Committee that they have the skills and ability to achieve the higher degree.

The Postgraduate Virtual Open Day usually takes place at the end of October. It’s a great opportunity to ask questions to admissions staff and academics, explore the Colleges virtually, and to find out more about courses, the application process and funding opportunities. Visit the  Postgraduate Open Day  page for more details.

See further the  Postgraduate Admissions Events  pages for other events relating to Postgraduate study, including study fairs, visits and international events.

Key Information

3-4 years full-time, 4-7 years part-time, study mode : research, doctor of philosophy, department of haematology, course - related enquiries, application - related enquiries, course on department website, dates and deadlines:, lent 2024 (closed).

Some courses can close early. See the Deadlines page for guidance on when to apply.

Easter 2024 (Closed)

Michaelmas 2024, easter 2025, funding deadlines.

These deadlines apply to applications for courses starting in Michaelmas 2024, Lent 2025 and Easter 2025.

Similar Courses

• Medical Science (Haematology) MPhil
• Stem Cell Biology Wellcome Trust PhD
• Biological Science (Stem Cell Biology) by thesis MPhil
• Stem Cell Biology PhD
• Medical Science (CIMR) PhD

Postgraduate Admissions Office

• Admissions Statistics
• Start an Application
• Applicant Self-Service

At a glance

• Bringing a family
• Current Postgraduates
• Cambridge Students' Union (SU)

University Policy and Guidelines

Privacy Policy

Information compliance

Equality and Diversity

Terms of Study

About this site

About our website

Privacy policy

© 2024 University of Cambridge

• Contact the University
• Accessibility
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• University A-Z
• Undergraduate
• Postgraduate
• Research news
• About research at Cambridge
• Spotlight on...

• Skip to main content

• All study levels /
• Postgraduate /
• Health and Medicine /
• Haematology

16 Universities offering Postgraduate Haematology courses abroad

More Information

Are you looking for Postgraduate courses in Haematology? Here you can find course providers offering full-time, part-time, online or distance learning options for courses abroad.

You've reached your limit of 10 Favourites

University of Chester

THE World Ranking: 1201

London Metropolitan University

Manchester metropolitan university.

THE World Ranking: 501

University of Greenwich

University of Galway

THE World Ranking: 301

The University of Sydney

THE World Ranking: 60

Keele University

University of Liverpool

THE World Ranking: 168

Middlesex University

Trinity College Dublin, the University of Dublin

THE World Ranking: 134

Sapienza University of Rome

THE World Ranking: 181

University of Cambridge

THE World Ranking: 5

• Study level:
• Postgraduate
• Graduate Certificates & Diplomas
• Masters Degrees
• Doctoral Degrees
• Study mode:
• Online/Distance

Filter your results

Tell us about you.

• Nationality Select country Select country
• My current qualification is from Select country Yes No Select country Select country
• Current qualification {0} is not applicable for the study level you selected below. Qualification Qualification
• Grade type (only one grade type for your qualification) Grade type Grade type
• My score (current or expected) Please select Please select Please select Please select Please select Please select

Tell us your preferences

• Subject Haematology
• Qualification Postgraduate

Destination

• Study options
• Annual tuition fees

Subject areas

Qualification.

• The UConn School of Business has grown to become one of the most comprehensive business schools in the country.
• NEW: Want to study in your home country for a foreign qualification? Find out more about cross-border study!